ivermectin oral / Generic mfg. 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...4142434445464748495051...129130»
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Assessment of anthelmintic effectiveness to control Fasciola hepatica and paramphistome mixed infection in cattle in the humid tropics of Mexico. (Pubmed Central) -  Mar 17, 2022   
    NITROX was the most effective in the control of trematodes, while other products, such as IVM + CLORS and TCBZ obtained values lower than 90%, which puts sustainable trematode control at risk. The presence of trematodes was observed on most farms, although the prevalence per herd was highly variable, which indicates that the trematodes F. hepatica and paramphistomes are endemic to the region and a suitable management programme is suggested to control infections caused by these parasites.
  • ||||||||||  remdesivir / Generic mfg., ivermectin oral / Generic mfg.
    Preclinical, Journal:  Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2. (Pubmed Central) -  Mar 16, 2022   
    Whilst the in vitro synergistic activity reported here does not support the clinical application of this combination treatment strategy, due to insufficient exposure of ivermectin in vivo, the data do warrant further investigation. Efforts to define the mechanisms underpinning the observed synergistic action, could lead to the development of novel therapeutic treatment strategies.
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Treatment of scabies (Pubmed Central) -  Mar 15, 2022   
    Diverse systematic reviews and meta-analysis have concluded that oral ivermectin is as effective and safe as topical permethrin. Mass drug administration of oral ivermectin is an excellent option for the management of scabies in communities with high prevalence, or for scabies outbreaks in institutions.
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients. (Pubmed Central) -  Mar 11, 2022   
    P1
    Patients & In 24 COVID-19 subjects refusing hospitalization with high-risk features, hypoxia and untreated moderate to severe symptoms averaging 9 days, the authors administered this novel combination of ivermectin, doxycycline, zinc and vitamins D and C. Results & All subjects resolved symptoms (in 11 days on average), and oxygen saturation improved in 24 h (87.4% to 93.1%; p = 0.001)...Triple combination therapy is safe and effective even when used in outpatients with moderate to severe symptoms. Clinical Trial Registration: NCT04482686 (ClinicalTrial.gov).
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Total Failure of Fenbendazole to Control Strongylid Infections in Czech Horse Operations. (Pubmed Central) -  Mar 11, 2022   
    Ivermectin and moxidectin demonstrated excellent efficacy (FECR 99.8-100%; 99.4-100 LLCI) in 45 and 23 operations, respectively, pyrantel embonate demonstrated sufficient efficacy in 15 operations and resistance was suspected in seven operations (FECR 88.1-99.1%; 72.5-98.5 LLCI)...Our data indicate an increase in the development of anthelmintic resistance, resulting in total failure of fenbendazole and a reduced efficacy of pyrantel embonate. Introducing advanced approaches of parasite control in the Czech Republic to slow the spread of anthelmintic resistance is thus needed.
  • ||||||||||  ivermectin oral / Generic mfg., ivermectin topical / Generic mfg.
    Journal:  Unusual presentation of crusted scabies with osteolysis in immunocompetent. (Pubmed Central) -  Mar 9, 2022   
    Introducing advanced approaches of parasite control in the Czech Republic to slow the spread of anthelmintic resistance is thus needed. We present a rare case of crusted scabies with osteolysis in an immunocompetent female.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Biomarker, Review, Journal:  Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies. (Pubmed Central) -  Mar 8, 2022   
    We strongly mandate to undertake a pharmacogenetic assessment for at least these drug-gene pairs (atazanavir-UGT1A1, ABCB1, SLCO1B1, APOA5; efavirenz-CYP2B6; nevirapine-HLA, CYP2B6, ABCB1; lopinavir-SLCO1B3, ABCC2; ribavirin-SLC28A2; tocilizumab-FCGR3A; ivermectin-ABCB1; oseltamivir-CES1, ABCB1; clopidogrel-CYP2C19, ABCB1, warfarin-CYP2C9, VKORC1; non-steroidal anti-inflammatory drugs (NSAIDs)-CYP2C9) in COVID-19 patients for advancing precision medicine...Although natural occurring compounds from different herbs against SARS-CoV-2 infection are favorable, however, accurate experimental investigation of these compounds is warranted to provide insightful information. Moreover, clinical considerations of drug-drug interactions (DDIs) and drug-herb interactions (DHIs) of the existing repurposed drugs along with pharmacogenetic (e.g., efavirenz and CYP2B6) and herbogenetic (e.g., andrographolide and CYP2C9) interventions, collectively called multifactorial drug-gene interactions (DGIs), may further accelerate the development of precision COVID-19 therapies in the real-world clinical settings.